Remarcate

Remarcate is a pre-clinical stage biotechnology company focused on developing novel small molecule inhibitors for the treatment of cancer. The company's primary focus is on targeting DNA-dependent protein kinase (DNA-PK), a critical enzyme in the non-homologous end joining (NHEJ) pathway of DNA double-strand break repair. By inhibiting DNA-PK, Remarcate aims to sensitize tumor cells to DNA-damaging agents such as radiotherapy and chemotherapy, potentially improving outcomes for patients with various solid tumors. The company is leveraging its expertise in medicinal chemistry and DNA repair biology to advance its lead programs toward clinical development.